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Background: Rosacea is a chronic inflammatory disorder affecting millions of individuals worldwide. Diagnosis is
based on signs and symptoms with management and treatment aimed to suppress inflammatory lesions, erythema,
and telangiectasia. While many clinical trials of rosacea exist, the lack of consensus in outcome reporting across all
trials poses a concern. Proper evaluation and comparison of treatment modalities is challenging. In order to address
the inconsistencies present, this project aims to determine a core set of outcomes which should be evaluated in all
clinical trials of rosacea.
Methods/design: This project will utilize a methodology similar to previous core outcome set research. A long list
of outcomes will be extracted over four phases: (1) systematic literature review, (2) patient interviews, (3) other
published sources, and (4) stakeholder involvement. Potential outcomes will be examined by the Steering Committee
to provide further insight. The Delphi process will then be performed to prioritize and condense the list of outcomes
generated. Two homogenous groups of physicians and patients will participate in two consecutive rounds of Delphi
surveys. A consensus meeting, composed of physicians, patients, and stakeholders, will be conducted after the Delphi
exercise to further select outcomes, taking into account participant scores. By the end of the meeting, members will
vote and decide on a final recommended set of core outcomes. For the duration of the study, we will be in
collaboration with both the Core Outcome Measures in Effectiveness Trials (COMET) and Cochrane Skin Group - Core
Outcome Set Initiative (CSG-COUSIN).
Discussion: This study aims to develop a core outcome set to guide assessment in clinical trials of rosacea. The end-
goal is to improve the reliability and consistency of outcome reporting, thereby allowing sufficient evaluation of
treatment effectiveness and patient satisfaction.
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Rosacea is a chronic dermatologic disorder with a preva-
lence of about 2 %, affecting 16 million Americans [1, 2].
Fair-skinned individuals of Celtic and European heritage
are most commonly affected, although all skin types may
develop the condition [1, 3]. The etiology of rosacea is un-
known and hence, diagnosis is often based on signs and
symptoms [1]. Primary features of rosacea include inflam-
matory papules/pustules, erythema, and telangiectasia [4].
Secondary features consist of burning, plaques, and
edema. Disease symptoms and lesions affecting the face
and other visible areas may have a negative impact on
health-related quality of life. Furthermore, patients with
rosacea are at an increased risk for significant comorbidi-
ties such as autoimmune diseases, inflammatory bowel
disease, and possibly cardiovascular disease [5–8].
In 2002, the National Rosacea Society Expert Committee
classified rosacea into four main subtypes: erythematote-
langiectatic, papulopustular, phymatous, and ocular [4, 9].
The erythematotelangiectatic subtype is the most com-
mon, with the phymatous subtype being rare. A variety of
treatments, including topical, systemic, and laser therapies,
have been utilized thus far. Topical treatments approved
by the US Food and Drug Administration (FDA) include
sodium sulfacetamide, ivermectin, azelaic acid, and metro-
nidazole [1]. Subantimicrobial-dose doxycycline is the only
FDA-approved systemic therapy for rosacea [1], but tetra-
cycline and isotretinoin are often used as well [3]. Mirvaso
(brimonidine tartrate) was approved in 2014 by the Euro-
pean Medicines Agency (EMA) to treat facial erythema
caused by rosacea [10]. Laser therapy is recommended for
the treatment of telangiectasia and rhinophyma.
Several trials are underway to evaluate new treatment
modalities for rosacea. According to ClinicalTrials.gov,
more than 100 trials relevant to rosacea are either in pro-
gress, actively recruiting, or complete [1, 11]. The 2015
Cochrane Review by van Zuuren assessed the efficacy and
safety of interventions for rosacea with impact on quality
of life [12]. Only 11 out of the 106 trials included in the
review assessed the effect of rosacea treatment on quality
of life, which made recommendations nearly impossible.
Heterogeneity in physician-assessed secondary review out-
comes, such as physician’s global evaluation, lesion counts,
and duration of remission were pervasive in the trials.
This inconsistency in outcomes measured across trials
poses a concern when evaluating the effects of different
interventions.There are few validated methods of assessing improve-
ment in rosacea, possibly due to the multiplicity of out-
comes collected. Selective outcome reporting bias, defined
as results-based selection of outcomes for publication, is a
problem in many clinical trials and affects the conclusions
of a significant proportion of systematic reviews [13].
Specific organizations have been formed to address
outcome reporting bias. The Core Outcome Measures in
Effectiveness Trials Initiative (COMET) brings together
researchers interested in developing a standardized set of
core outcomes in various health-related fields [14]. A core
outcome set (COS) is defined as an agreed minimum set
of outcomes that is recommended to be measured and re-
ported in all clinical trials of a given condition or disease.
The implementation of a COS may reduce the risk of
selective outcome reporting and allow for more important
outcomes to be assessed.
Another group, the Cochrane Skin Group - Core Out-
come Set Initiative (CSG-COUSIN), was created specifically
to address COSs in dermatology by examining outcome
measures in current research [15]. CSG-COUSIN builds on
the experiences of the Harmonizing Outcome Measures
for Eczema (HOME) initiative, which also developed a
roadmap to guide the process of COS development and
implementation [16–21]. Similar to other initiatives,
the CSG-COUSIN group hopes to develop standard-
ized, evidence-based core outcome sets which can be
utilized in all clinical trials.
While COS are under development for several dermato-
logic conditions, work has yet to be done to identify core
outcomes specific for rosacea. In order to minimize dupli-
cation, this study has been registered with the COMET
and CSG-COUSIN organizations so researchers are aware
of our ongoing efforts and may participate if interested.
Objective
The aim of this study is to develop an international
COS that is relevant to clinical trials of rosacea based
on the systematic synthesis of peer-reviewed research
evidence; preferences from relevant stakeholder groups,
including patients, clinicians, regulators; and structured
consensus processes involving all relevant perspectives
[21]. Objectives include first determining what should
be measured and second, how it should be measured in
rosacea clinical trials. The selected outcomes that may be
recommended for inclusion in all rosacea research trials
will be a minimum set that will not preclude inclusion of
Fig. 1 Flowchart of the study design
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Methods/design
The development of this COS adheres to the recommen-
dations provided by the COMET and CSG-COUSIN
initiatives [14, 21]. Reporting conforms to the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) checklist (see Additional file 1). Figure 1
provides a brief overview of our study design.
Scope of this COS
This COS is intended as the global/international stand-
ard for clinical trials examining the efficacy of various
treatments for rosacea as evaluated by physicians, pa-
tients, and others invested in its results. The COS to be
developed will not be population-specific and may be
applied to individuals of all ages, genders, skin types,
races, and ethnicities. Similarly, all rosacea-specific inter-
ventions, including topical, systemic, and laser therapy,
may be evaluated using the outcomes generated from this
study.
Identification of outcomes
The list of outcomes currently reported will be generated
over four phases.
 First, a systematic literature review will be performed
to extract outcomes assessed in published randomized
controlled trials. Cochrane reviews will also be
examined for outcome inclusion
 Second, patient interviews will be conducted to
determine patient-centered outcomes which should
be assessed
 Third, other sources, such as clinical trials registries
and rosacea educational and treatment brochures,
will be reviewed to ensure all outcomes have been
documented
 Prior to the development of a final list of outcomes,
stakeholders will be invited to provide insight into
further outcomes that they would like included
Literature review
A systematic literature review using PubMed, Embase,
CENTRAL, and CINAHL will be conducted using
search terms related to rosacea. Included studies will be
randomized controlled trials of rosacea, regardless of
study quality or bias. Duplicate studies which cross over
from different databases will be removed and included
only once. Each article will then be extracted. Authors,
year of publication, source of funding, and treatment ve-
hicle will be documented among other study characteris-
tics. In terms of study design, items such as length of
follow-up, treatment duration, results, outcomes, and
Table 1 Summary of stakeholder involvement
Key stakeholders
Physicians (including dermatologists, international providers,
physicians of other health care fields)
Patients
Drug and device safety regulators (e.g., FDA, EMA)
National Rosacea Society/support groups
Pharmacologists/pharmacists
Industry scientists
Nurses, physician assistants, or other health care providers
EMA European Medicines Agency, FDA US Food and Drug Administration
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comes extracted from published studies will then be
placed into appropriate domains by two investigators.
Domains will be determined based on the outcomes
extracted and will encompass treatment efficacy, adverse
events, and quality of life. Outcomes that are very simi-
lar or synonymous in nature will be collapsed and listed
only once. If two outcomes are the same, the shorter
version of the name will be applied. Subcategories will
be listed appropriately to further stratify a domain. If
several similar entries are combined, the constituents
will be listed in brackets after the new category.
Combining and collapsing of outcomes, while necessary,
will be performed in moderation to preserve the content
and significance of distinct outcomes.
Patient-centered outcomes
In order to encompass patient-centered outcomes, a
semistructured interview will be conducted to explore
the domains identified in the literature review as well
as other potential patient identified outcomes. Approxi-
mately 10-15 patients with rosacea will be interviewed.
A global context will be provided by including partici-
pants both in the United States and internationally.
Informed consent will be obtained from each partici-
pant. Open-ended questions will allow for patient ex-
pression of relevant outcomes, which may provide
identify outcomes not noted in established quality of
life questionnaires or prior studies. Interviews will be
audio-recorded, transcribed, and coded to allow accur-
ate and complete capturing of outcomes mentioned.
Through the addition of outcomes ascertained during
the interviews, we hope to provide a more complete
account of issues important to patients.
Additional sources
Examination of other published sources, including clinical
trials registries and Cochrane reviews, will be conducted
to gather outcomes related to rosacea. Pamphlets and bro-
chures describing treatments and reported outcomes will
be extracted, and outcomes detected will be included in
the final list of outcomes.
Stakeholder involvement
Stakeholders, or those invested in the development of a
COS in rosacea, will also be included in the decision
process (Table 1). Dermatologists, drug and device safety
regulators (e.g., FDA, EMA), patient support groups (e.g.,
National Rosacea Society), pharmacologists, pharmacists,
and industry scientists associated with drugs and devices
for treatments of rosacea are potential members who can
provide input regarding what outcomes that they feel
should be represented. Nurses, physician assistants, andother health care practitioners may also be included to en-
hance further discussion.
Potential outcomes
The long list of outcomes obtained from the steps
described above will then be examined by the Steering
Committee, composed of four dermatologists: Drs. Murad
Alam (Northwestern University), Ian A. Maher (Saint
Louis University), Joseph F. Sobanko (University of
Pennsylvania), and Todd V. Cartee (Pennsylvania State
University). These members may add or remove outcomes
as they deem suitable to be included in the list prior to the
Delphi process. The Steering Committee members will
not join in the Delphi process, but members will be in-
vited to participate in the final consensus meeting.
Delphi overview
Delphi surveys have been used in prior COS research
[22]. Surveys can be conducted online through the use
of specialized software. The Delphi process involves a
series of rounds of data collection and analysis to con-
dense the opinions of individuals into a group consen-
sus. Responses to each round are collected, analyzed,
and then redistributed to participants in successive
rounds. We plan to conduct two Delphi rounds prior to
the consensus meeting.
Participants
Two homogenous groups composed of patients or
physicians, respectively, will participate in the Delphi
exercises. Groups will consist of approximately 30 indi-
viduals to provide a greater diversity of input and ac-
count for potential dropouts. A global context will be
provided by including patients from both the United
States and internationally; physicians from across the
country and internationally will be included in the other
group. Prior to the exercise, details of the COS will be
summarized in plain language. Demographic and occu-
pational information, including years of experience, field
of interest, and position, will be obtained. Consent will
be assumed if participants complete the questionnaire.
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survey with email reminders at the 1- and 2-week marks.
For each round, the number of participants invited and
those who completed the surveys will be documented
and attrition assessed.
Delphi rounds
In the first Delphi, the complete list of outcomes gath-
ered from the literature review, patient interviews, stake-
holder interaction, and other sources will be presented
for rating. Outcomes will be listed randomly after each
round to avoid any influence the display order may have
when scoring. Using a scale devised by the Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) working group, participants will score
each outcome on a scale from 1 to 9 with “9” being crit-
ically important and “1” being not very important [23].
For the first round, the additional option of “10” will be
available if participants are unsure of its need for inclu-
sion.. Participants will be asked to focus on ranking the
most valued outcomes high and excluding outcomes of
lesser importance. They will also have the option to add
outcomes to the list that they feel should be included.
All outcomes will be carried to the subsequent round.
Descriptive statistics will be used to analyze the data
from the two groups. Responses from both stakeholder
groups will be summarized and fed back to the partici-
pants after the first round, allowing participants to
change their score in light of others’ insights. At the
same time, participants will be asked to identify new
outcomes and determine if outcomes should be com-
bined. New outcomes will be added to the list for the
next round if two or more participants suggest its inclu-
sion. Any uncertainties will be directed to the Steering
Committee for adjudication.
In round 2 of the Delphi exercise, participants will
again score the outcomes on a scale from 1 to 9, follow-
ing the same format as the previous Delphi exercise.
The end result of the Delphi should consist of a more
simplified set of outcomes that will be further examined
at the consensus meeting.
Consensus meeting
Prior to solidifying a core set of outcomes, a face-to-face
consensus meeting will be held to discuss the results of
the Delphi rounds. An independent facilitator will chair
the meeting to finalize the outcomes. Physicians, patients,
and other stakeholders will be invited to the meeting to
provide insight on the process. Results from each round of
the Delphi survey will be presented. In terms of consen-
sus, if 70 % of participants rank the outcome 7, 8, or 9
with less than 15 % scoring it 1–3, the outcome will be
retained in the consensus pool [24]. Outcomes will be
removed from the consensus list if 70 % or more of theparticipants rank the outcome 1–3 and less than 15 %
rank the outcome 7, 8, or 9.
Feedback regarding the consensus-derived set of out-
comes will then be elicited with the assistance of a
trained moderator. Using live polling software, items will
anonymously be voted “Yes” or “No” for inclusion into
the final core set of outcomes. By the end of the meet-
ing, the goal is to create a core set of outcomes which
can be agreed upon by all stakeholders, patients, and
physicians.
Core outcome measures
Once a COS has been developed, the Harmonizing
Outcome Measures for Eczema (HOME) roadmap will
be utilized for developing or selecting a core set of
measures to track the outcomes selected [21]. Initial
steps include identifying outcome domains and current
instruments used to measure those specific domains.
Special focus will be directed at systematically identify-
ing relevant outcome measurements through a system-
atic review covering multiple databases. Quality of the
studies will be assessed by rating their validity, reliabil-
ity, responsiveness to change, and interpretability. The
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) framework will
be utilized for guidance.
In order to determine which measurements are suit-
able per outcome domain, a consensus meeting with
key stakeholders, patients, and clinicians will be held
[21]. Results from the systematic review will be pro-
vided to guide discussion. Attendees will then judge
the measures based on how valid, reliable, and feas-
ible they may be for assessing each core outcome
domain. If evidence for a particular measurement in-
strument is inadequate, it may be necessary to de-
velop a new instrument. At the end of the consensus
meeting, relevant stakeholders will vote to determine
which measures should be included. An outcome meas-
urement instrument should be recommended for each
core outcome domain.
Discussion
There is currently no COS relevant to clinical trials of
rosacea. With a lack of standardization in outcomes
assessed, the potential for reporting bias exists. Further,
selection of outcomes is crucial for properly comparing
and evaluating the effectiveness of different treatment
interventions.
The proposed COS for rosacea aims to reduce the in-
consistency of outcomes and outcome measurements
across relevant trials. Through the use of COSs, we
hope to hasten refinement and adoption of therapies
for rosacea that address factors important to key stake-
holders, particularly patients and physicians.
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The development of the COS is active and ongoing in its
initial phase of outcome extraction.
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